Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,585 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Urinary Bladder Diseases\Urologic Diseases Clear all

Conditions: Overactive Bladder, Overactive Detrusor, Urgency-Frequency Syndrome, UTI
Interventions: Extended Urine Culture; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: nicotine lozenge, nicotine patch; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Miami Beach, Florida • Augusta, Georgia + 7 more

Conditions: Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions: Administration of autologous adipose derived SVF; Procedure
Lead sponsor: Elliot Lander; Industry
Eligibility: 16 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rancho Mirage, California

Conditions: Urinary Incontinence
Interventions: Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material; Drug · Behavioral
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 51
States / cities: Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 48 more

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cystoscopy, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab, Transurethral Resection of Bladder Tumor; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 381
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 257 more

Conditions: Overactive Bladder
Interventions: Retrospective chart review; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Orange, California

Conditions: Overactive Bladder
Interventions: botulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal saline (Placebo); botulinum toxin Type A (200U), Normal saline (Placebo); botulinum toxin Type A (300U); Biological · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Middlebury, Connecticut

Conditions: Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia
Interventions: CDX-1140, CDX-301, pembrolizumab, Chemotherapy; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 11
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more

Conditions: Bladder Cancer
Interventions: Not listed
Lead sponsor: David Latini; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Urethral Neoplasms, Neoplasms, Urethral, Cancer of the Urethra, Urethral Cancer
Interventions: Gemcitabine, Carboplatin, Lenalidomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Metastatic Bladder Cancer
Interventions: RX-3117; Drug
Lead sponsor: Processa Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 12
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 9 more

Conditions: Urinary Dysfunction, Lower Urinary Tract Symptoms, Urinary Tract Infections, Urinary Tract Infections in Children
Interventions: Bladder Health Education; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 5 Years to 10 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2033
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Bladder Cancer, Uterine Cancer, Kidney Cancer, Renal Pelvis Cancer, Pancreatic Cancer, Liver Cancer, Stomach Cancer, Ovarian Cancer, Esophageal Cancer
Interventions: Blood Sample Collection; Other
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 5,133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 119
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 106 more

Conditions: Bladder Pain Syndrome, Female Sexual Dysfunction
Interventions: Onabotulinum toxin A, Conservative management (dietary and behavioral); Drug · Behavioral
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumors
Interventions: RMC-5552; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Irvine, California • Sacramento, California • San Francisco, California + 5 more

Conditions: Overactive Bladder, Urinary Tract Infections
Interventions: Periprocedural Antibiotics, Extended Antibiotics, Injection of OnabotulinumtoxinA (BTX-A); Drug · Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer, Pancreatic Cancer, Liver Cancer, Renal Cancer, Bladder Cancer, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions: Pillars4Life; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Interstitial Cystitis, Painful Bladder Syndrome
Interventions: PD 0299685 at 15mg BID, PD 0299685 at 30mg BID, placebo for PD 0299685; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 23
States / cities: Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 20 more

Conditions: Bladder Cancer
Interventions: Abemaciclib; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Urinary Bladder, Overactive, Urinary Incontinence
Interventions: onabotulinumtoxinA, Placebo (saline); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 31
States / cities: Laguna Hills, California • Los Angeles, California • Orange, California + 27 more

Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 110 Years
Enrollment: 999,999 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2099
U.S. locations: 42
States / cities: Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Chronic Bacterial Prostatitis, Asymptomatic Inflammatory Prostatitis, Painful Bladder Syndrome, Cystitis, Interstitial
Interventions: Genomic and proteomic biomarker discovery; Genetic
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urinary Retention
Interventions: Tamsulosin; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 55 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Brick, New Jersey • Manahawkin, New Jersey • Neptune City, New Jersey + 1 more

Search by objective public record fields.

Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive Bladder

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Quality of Life and Symptom Management in Patients With Bladder Cancer

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

School-Based Bladder Health Intervention

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection

Pillars4Life Trial

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

Integrated Cancer Repository for Cancer Research

Diagnostic Challenges in IC (and Male CPPS)

Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery